Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Weak Chinese Manufacturing Survey Weighs on Markets

By KEN SWEET, AP Business Writer | May 3, 2016

NEW YORK (AP) — A weak Chinese manufacturing survey weighed on U.S. and European markets on Tuesday, renewing concerns that the world’s second-largest economy might be slowing down.

KEEPING SCORE: The Dow Jones industrial average lost 193 points, or 1.1 percent, to 17,696 as of 10 a.m. Eastern. The Standard & Poor’s 500 index lost 24 points, or 1.2 percent, to 2,057 and the Nasdaq composite fell 63 points, or 1.3 percent, to 4,753.

CHINA WORRIES: The Caixin magazine’s purchasing managers’ index for the manufacturing sector declined to a reading of 49.4 points from March’s reading of 49.7. A number below 50 indicates that manufacturing is contracting. Worries about China were largely responsible for the turmoil in global financial markets in the early part of the year.

AUSTRALIA WORRIES: Compounding the worries about China, Australia’s central bank unexpectedly cut interest rates to a record low. Australia’s economy has been battered as commodity prices have plummeted and other parts of the developed world have slowed down. The news sent the Australian dollar down more than 2 percent.

PULLED DEPOSITS: The global economic worries hit two of the hardest-hit sectors this year: energy stocks and banks. Energy companies in the S&P 500 slumped 2.1 percent, the most in the index, and financial stocks were close behind with a drop of 1.9 percent.

BLUE PILL: Pfizer jumped 93 cents, or 2.8 percent, to $33.73 after the company reported solid first quarter earnings that beat analysts’ estimates. Pfizer saw big sales gains in some of its newest drugs, including Lyrica and vaccine Prevnar 13.

ENERGY: Benchmark U.S. crude oil lost 70 cents to $44.04 a barrel on the New York Mercantile Exchange. Brent crude, the international standard, fell 56 cents to $45.27 a barrel in London.

BONDS, CURRENCIES: U.S. government bond prices rose sharply. The yield on the 10-year Treasury note fell to 1.79 percent from 1.87 percent late Monday. The euro rose to $1.1548 from $1.1523. The dollar fell to 105.97 yen from 106.45 yen.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news! 


Filed Under: Drug Discovery

 

Related Articles Read More >

If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
Physician in a white coat reviewing information on a tablet with a patient in an exam room.
What real-world data shows about current cancer care
Roche Towers, Basel, Switzerland
Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE